Nightingale Health’s blood analysis shows great promise for preventative COVID-19 and Pneumonia Risk Detection
Finland’s Nightingale Health , an innovator in blood-testing technology, today announced that their analyses of the first 125,000 blood samples from the UK Biobank data shows that biomarkers which indicate poor metabolic health and systemic inflammation, can predict the severity of COVID-19 and pneumonia years in advance. The samples screened were taken 10 years before the pandemic and the findings could, therefore, be used as predictive tools and provide immense value to institutions, companies and the society at large, as we